Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib and Ofatumumab or Ibrutinib in Relapsed/Refractory CLL
NCT02614508Phase 1Terminated
- Sponsor
- Emory University
- Start
- Jan 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of buparlisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts), sponsored by Emory University. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2016; status: terminated.
02
Drugs
buparlisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02614508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614508.